Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults

Human Vaccines

Volumn 5, Issue 12, 2009, Pages

  Weston, Wayde M ^a   Chandrashekar, Vijayalakshmi ^a   Friedland, Leonard R ^a   Howe, Barbara ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adult; Booster immunization; Diphtheria tetanus acellular pertussis vaccines; Influenza vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; ANTITOXIN; BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE PRURITUS; INJECTION SITE RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; TERATOGENICITY; TETANUS; TREATMENT RESPONSE; VACCINATION; BLOOD; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; UNITED STATES;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTITOXINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; UNITED STATES; VACCINATION;

EID: 85046915712     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.9961     Document Type: Article

References (27)

1. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 2007; 32:17-9.
2. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634-42.
3. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2006; 26:238-42.
4. Kretsinger K, Broder KR, Cortese MM, et al. Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among healthcare personnel. MMWR Recomm Rep 2006; 55:1-37.
5. Fiore AE, Shay DK, Broder K, et al. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 2008; 57.
6. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid, and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009; 27:765-72.
7. Boostrix™ Prescribing Information. Available at http://us.gsk.com/products/assets/us-boostrix.pdf. Accessed 2009.
8. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007; 25:3464-74.
9. Food and Drug Administration (FDA). Vaccines and Related Biological Products Advisory Committee, Bethesda, Maryland: 5-June-1997. Center for Biologics Evaluation and Research, Bethesda MD, USA; 1997. Available at http://www.fda.gov/ohrms/dockets/ac/97/ transcpt/3300t1.pdf. Accessed 2009.
10. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003-11.
11. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006; 117:1084-93.
12. Schmitt HJ, von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
13. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr 1996; 129:695-701.
14. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55.
15. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555-63.
16. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004; 190:535-44.
17. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
18. Hellwig SM, Rodriguez ME, Berbers GA, van de Winkel JG, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003; 188:738-42.
19. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16:1901-6.
20. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 2006; 149:603-10.
21. High K. Immunizations in older adults. Clin Geriatr Med 2007; 23:669-85.
22. Al-Sukhni W, Avarino P, McArthur MA, McGeer A. Impact of public vaccination programs on adult vaccination rates: Two examples from Ontario, Canada. Vaccine 2008; 26:1432-7.
23. Centers for Disease Control and Prevention (CDC). State-specific influenza vaccination coverage among adults aged > or =18 years - United States, 2003-04 and 2005-06 influenza seasons. MMWR 2007; 56:953-9.
24. Coudeville L, Van Rie A, Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008; 136:604-20.
25. McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE; Advisory Committee on Immunization Practices. Use of standing orders programs to increase adult vaccination rates. MMWR Recomm Rep 2000; 49:15-6.
26. Prosser LA, O'Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics 2008; 26:163-78.
27. WHO Manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5. Available at http://www.wpro.who.int/NR/rdonlyres/ EFD2B9A7-2265-4AD0-BC98-97937B4FA83C/0/manualonanimalaidiagnosisandsurveillance. pdf. Accessed 2009.